Synthorx raises $63 million in series C

Synthorx Inc. (La Jolla, Calif.) raised $63 million in a series C round led by new investor OrbiMed Advisors. Fellow new investors Medicxi and Osage University Partners also participated in the round, as did existing investors Avalon Ventures, RA Capital and Correlation Ventures.

Synthorx is using synthetic biology to develop a pipeline of Synthorin cytokines. Synthorins contain unnatural amino acid sequences and are engineered to have extended half-lives and increased receptor specificity. The company, which launched in 2014, has created a strain of E. coli that incorporates the nucleotides into cellular processes to produce synthetic proteins by design...